Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer

NCT06065813 is registered in ClinicalTrials.gov with Northern Jiangsu People's Hospital as lead sponsor.

NCT NCT06065813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer
Lead sponsor
Northern Jiangsu People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 8, 2022
Completion date
May 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, neoadjuvant therapy, non-small cell lung cancer, radiotherapy